BioCentury | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

...Cadent Therapeutics Inc. (Cambridge, Mass.) hired Jodie Morrison as CEO. Morrison was interim CEO of Keryx Biopharmaceuticals Inc....
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...31 to pursue other interests. Sullivan was SVP of corporate affairs at Keryx Biopharmaceuticals Inc. Last month, Keryx...
BioCentury | Nov 19, 2018
Company News

Management tracks: Brickell, Genevant

...will serve as chairperson of the enlarged Akebia Therapeutics Inc. (NASDAQ:AKBA), after its merger with Keryx Biopharmaceuticals Inc....
BioCentury | Aug 30, 2018
Company News

Management tracks: Lilly, Kiadis

...who is SVP and CFO at Keryx Biopharmaceuticals Inc. (NASDAQ:KERX). Holmes plans to make the transition once Keryx...
...completes its planned merger with Akebia Therapeutics Inc. (NASDAQ:AKBA) this year (see “Renal Plays Akebia, Keryx...
...was an adviser at patient engagement platform CheckedUp (New York, N.Y.). BC Staff Akebia Therapeutics Inc. Harvard Bioscience Inc. Keryx Biopharmaceuticals Inc. Kiadis...
BioCentury | Jun 29, 2018
Company News

Renal plays Akebia, Keryx merging

...Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined...
...with one chronic kidney disease compound on the market and another in Phase III testing. Keryx...
...Akebia shareholders will own the balance. Keryx shareholders will receive 0.37433 Akebia shares for each Keryx...
BioCentury | Jun 28, 2018
Company News

Renal plays Akebia, Keryx merging

...Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined...
...Akebia lost $1.02 (10%) to $9.36 on Thursday, while Keryx fell $0.85 (19%) to $3.63. Keryx...
...Akebia shareholders will own the balance. Keryx shareholders will receive 0.37433 Akebia shares for each Keryx...
BioCentury | Nov 10, 2017
Clinical News

FDA approves Keryx's Auryxia for non-dialysis-dependent CKD

...approved in the U.S. to control serum phosphorous levels in patients with CKD on dialysis. Keryx...
...but excluding the rest of the Asia-Pacific region, from Panion & BF Biotech Inc. (TPEx-E:1760). Keryx Biopharmaceuticals Inc....
...Product: Auryxia (Fexeric - EU, Riona - Japan) ferric citrate (KRX-0502, JTT-751) Business: Hematology Allison Johnson Auryxia ferric citrate Fexeric JTT-751 KRX-0502 Riona Keryx Biopharmaceuticals Inc. Panion...
BioCentury | Nov 7, 2017
Financial News

Keryx sags after withdrawing guidance

...revenues of $15 million for the quarter, falling short of the $18 million consensus estimate. Keryx...
...than expected due to payer dynamics and slower growth in prescriptions than expected. In July, Keryx...
...oral ferric iron-based phosphate binder to treat iron deficiency anemia in patients with non-dialysis-dependent CKD. Keryx...
BioCentury | Mar 9, 2017
Clinical News

Auryxia regulatory update

...FDA accepted for review an sNDA from Keryx for Auryxia ferric citrate to treat iron deficiency...
...U.S. to control serum phosphorous levels in patients with end-stage renal disease (ESRD) on dialysis. Keryx...
...excluding the rest of the Asia-Pacific region, from Panion (see BioCentury, Feb. 20, 2006 ). Keryx Biopharmaceuticals Inc....
BioCentury | Feb 15, 2017
Distillery Therapeutics

Infectious disease

...increased survival. Next steps could include testing Sulonex in additional models of sepsis. In 2008, Keryx Biopharmaceuticals Inc....
Items per page:
1 - 10 of 368
BioCentury | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

...Cadent Therapeutics Inc. (Cambridge, Mass.) hired Jodie Morrison as CEO. Morrison was interim CEO of Keryx Biopharmaceuticals Inc....
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...31 to pursue other interests. Sullivan was SVP of corporate affairs at Keryx Biopharmaceuticals Inc. Last month, Keryx...
BioCentury | Nov 19, 2018
Company News

Management tracks: Brickell, Genevant

...will serve as chairperson of the enlarged Akebia Therapeutics Inc. (NASDAQ:AKBA), after its merger with Keryx Biopharmaceuticals Inc....
BioCentury | Aug 30, 2018
Company News

Management tracks: Lilly, Kiadis

...who is SVP and CFO at Keryx Biopharmaceuticals Inc. (NASDAQ:KERX). Holmes plans to make the transition once Keryx...
...completes its planned merger with Akebia Therapeutics Inc. (NASDAQ:AKBA) this year (see “Renal Plays Akebia, Keryx...
...was an adviser at patient engagement platform CheckedUp (New York, N.Y.). BC Staff Akebia Therapeutics Inc. Harvard Bioscience Inc. Keryx Biopharmaceuticals Inc. Kiadis...
BioCentury | Jun 29, 2018
Company News

Renal plays Akebia, Keryx merging

...Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined...
...with one chronic kidney disease compound on the market and another in Phase III testing. Keryx...
...Akebia shareholders will own the balance. Keryx shareholders will receive 0.37433 Akebia shares for each Keryx...
BioCentury | Jun 28, 2018
Company News

Renal plays Akebia, Keryx merging

...Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined...
...Akebia lost $1.02 (10%) to $9.36 on Thursday, while Keryx fell $0.85 (19%) to $3.63. Keryx...
...Akebia shareholders will own the balance. Keryx shareholders will receive 0.37433 Akebia shares for each Keryx...
BioCentury | Nov 10, 2017
Clinical News

FDA approves Keryx's Auryxia for non-dialysis-dependent CKD

...approved in the U.S. to control serum phosphorous levels in patients with CKD on dialysis. Keryx...
...but excluding the rest of the Asia-Pacific region, from Panion & BF Biotech Inc. (TPEx-E:1760). Keryx Biopharmaceuticals Inc....
...Product: Auryxia (Fexeric - EU, Riona - Japan) ferric citrate (KRX-0502, JTT-751) Business: Hematology Allison Johnson Auryxia ferric citrate Fexeric JTT-751 KRX-0502 Riona Keryx Biopharmaceuticals Inc. Panion...
BioCentury | Nov 7, 2017
Financial News

Keryx sags after withdrawing guidance

...revenues of $15 million for the quarter, falling short of the $18 million consensus estimate. Keryx...
...than expected due to payer dynamics and slower growth in prescriptions than expected. In July, Keryx...
...oral ferric iron-based phosphate binder to treat iron deficiency anemia in patients with non-dialysis-dependent CKD. Keryx...
BioCentury | Mar 9, 2017
Clinical News

Auryxia regulatory update

...FDA accepted for review an sNDA from Keryx for Auryxia ferric citrate to treat iron deficiency...
...U.S. to control serum phosphorous levels in patients with end-stage renal disease (ESRD) on dialysis. Keryx...
...excluding the rest of the Asia-Pacific region, from Panion (see BioCentury, Feb. 20, 2006 ). Keryx Biopharmaceuticals Inc....
BioCentury | Feb 15, 2017
Distillery Therapeutics

Infectious disease

...increased survival. Next steps could include testing Sulonex in additional models of sepsis. In 2008, Keryx Biopharmaceuticals Inc....
Items per page:
1 - 10 of 368